Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesHigh-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors
Annals of Oncology, 10/14/09
Lorch A et al. – Survival after high-dose chemotherapy (HDCT) as second-salvage treatment (SST) in multiple relapsed germ-cell tumors (GCTs). HDCT can induce remissions in patients with multiple relapsed GCTs with a long-term survival rate of 17%.
Methods- Existing databases in Berlin and Marburg of HDCT trials from 1989 to 2008 retrospectively screened
- Among 534 patients, 71 of 534 (13%) patients scheduled for HDCT having failed previous conventional-dose first-line and first-salvage chemotherapy regimens
- 49 patients who had received at least cisplatin plus etoposide first-line as well as conventional-dose cisplatin-based first-salvage regimens and diagnosed after 1 January 1990 further analyzed
- Median age at SST 32 years (range 19–52 years)
- Median follow-up for surviving patients 4 years (range 1.7–8.5 years)
- 3 of 49 (6%) patients either progressed or died before scheduled HDCT
- Remaining 46 of 49 (94%) received either single or sequential HDCT
- Rate of favorable responses to HDCT was 27 of 49 (55%)
- 9 patients remain alive and free of progression
- 1 additional patient lost to follow without progression at 4 years
- Projected overall survival rate at 5 years was 17%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Ovarian cancer screening and early detection
Women's Health, 11/04/09
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
The Lancet, 11/23/09
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09
Sponsor
Article Search
Sponsor
Sponsor